Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer

Development of a next generation allogeneic CAR-T cell platform without gene editing

Development of a next generation allogeneic CAR-T cell platform without gene editing

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Differential effects of target ligands upon NKG2D CAR T cell activation

Differential effects of target ligands upon NKG2D CAR T cell activation

Generating Allogeneic CAR T cells without Gene Editing

Generating Allogeneic CAR T cells without Gene Editing

Overcoming target‐driven fratricide for CAR‐T cell therapy

Overcoming target‐driven fratricide for CAR‐T cell therapy

Functional screening of different anti-B7H6 CAR designs

Functional screening of different anti-B7H6 CAR designs

The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo

The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo

Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors

Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors